Animal models of hospital-acquired pneumonia: current practices and future perspectives

Kenny Bielen1,2, Bart 's Jongers1,2, Surbhi Malhotra-Kumar2

  • 1Molecular Pathology Group, Faculty of Medicine and Health Sciences, Laboratory of Cell Biology and Histology, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium.

Insights

This review guides researchers in selecting animal models for studying pneumonia, particularly infections caused by Pseudomonas aeruginosa. It details various models to advance understanding and treatment of hospital-acquired pneumonia.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Translational Medicine

Background:

  • Lower respiratory tract infections cause significant global mortality and morbidity.
  • Nosocomial pneumonia, especially ventilator-associated pneumonia (VAP), is a severe complication in hospital settings.
  • Pseudomonas aeruginosa is a key pathogen in VAP and chronic cystic fibrosis lung infections.

Purpose of the Study:

  • To guide investigators in selecting appropriate animal models for pneumonia research.
  • To compare characteristics of different animal pneumonia models using P. aeruginosa.
  • To highlight the importance of well-defined endpoints for translational research.

Main Methods:

  • Review of existing literature on animal models of pneumonia.
  • Description and comparison of acute, VAP, and biofilm pneumonia models.
  • Discussion of humanized animal models for studying bacterial virulence and host response.

Main Results:

  • Various animal models (acute, VAP, biofilm) have advanced understanding of pneumonia pathogenesis.
  • P. aeruginosa serves as a relevant model organism for hospital-acquired pneumonia studies.
  • Humanized models offer potential for studying virulence factors and cytokine production.

Conclusions:

  • Appropriate animal models are crucial for understanding pneumonia and developing new therapies.
  • Well-defined endpoints are essential for translating animal model findings to clinical practice.
  • Future research may benefit from humanized models for studying host-pathogen interactions in bacterial pneumonia.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
944
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.7K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.1K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.0K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
3.6K